Active Surveillance for Cancer of the Prostate (ASCaP)

Description

Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with low-risk, localized lesions, with curative treatment of those whose tumors show substantial progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative treatment of men with progressive prostate cancer.

Conditions

Prostate Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with low-risk, localized lesions, with curative treatment of those whose tumors show substantial progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative treatment of men with progressive prostate cancer.

The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.

Active Surveillance for Cancer of the Prostate (ASCaP)

Condition
Prostate Cancer
Intervention / Treatment

-

Contacts and Locations

Los Angeles

University of California Los Angeles, Los Angeles, California, United States, 90095

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Histologically confirmed adenocarcinoma of the prostate.
  • 2. Clinically localized prostate cancer: T1-2, NX or N0, MX or M0.
  • 3. No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy).
  • 4. Patient has elected Active Surveillance as preferred management plan for prostate cancer.
  • 5. Patient consent has been obtained according to local Institutional Review Board .
  • 6. Patient is accessible and compliant for follow-up.
  • 1. Unwillingness or inability to undergo serial prostate biopsy.
  • 2. Overall life expectancy less than 2 years
  • 3. Advanced prostate cancer

Ages Eligible for Study

30 Years to 85 Years

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Jonsson Comprehensive Cancer Center,

Leonard S Marks, M.D., PRINCIPAL_INVESTIGATOR, University of California, Los Angeles

Study Record Dates

2028-12